secwatch.observer — SEC 8-K summary
======================================

Issuer:     enGene Therapeutics Inc. (ENGN)
CIK:        0001980845
Form:       8-K
Filed at:   2024-01-29T23:59:59+00:00
Accession:  0000950170-24-008123
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

enGene reports FY2023 net loss $104.7M; Phase 1 LEGEND study 68% CR rate, interim data mid-2024
--------------------------------------------------------------------------------

- FY2023 net loss $104.7M ($151.22/share) vs $29.0M ($44.30) in FY2022; operating expenses $26.0M.
- Phase 1 LEGEND study in BCG-unresponsive NMIBC met endpoints; 68% complete response at 3 months (n=22); pivotal Phase 2 enrolling, interim data mid-2024.
- Completed reverse merger with FEAC and upsized PIPE financing, net proceeds ~$109M; launched on Nasdaq Nov 1, 2023.
- Expanded Hercules debt facility to $50M ($22.5M funded); cash $81.5M at Oct 31, 2023, runway into Q2 2025.
- Leadership hires: Alex Nichols (President/COO), Richard Bryce (CMO), Ryan Daws (CFO), Lota Zoth (Board).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1980845/000095017024008123/0000950170-24-008123-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1980845/000095017024008123/engn-20240129.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-008123

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer